BIOKÉ Webshop

Forgot password?Login

No account?

Enjoy the advantages of a BIOKÉ webshop account.

Invalid login

Your credentials are incorrect or you are trying to login with a non-existing webshop account. Our website shows product prices without login! Therefore webshop accounts that were only used to view prices have been deleted.

Please create a new account with your shipping and billing details if you would like to be able to order or view your discount.

Webshop under construction

Due to technical maintenance the webshop is closed until January 3, 2024. We wish you a successful 2024!

Forgot your password?

Don't worry. Enter your username and we will send you a link to reset your password if an associated user is found.

Need help?

Have trouble resetting your password? Contact us and we will help you.

You've got mail

You will receive an e-mail containing a link to start the recovery procedure within minutes.

Change password

Change your password to something secure.


Your password has been changed.

Password sent

You will receive an e-mail from us containing your new password in the coming minutes.

Please change your password to something memorable and secure upon logging in.


Sign out

Cell Signaling Technology Releases Four Monoclonal Antibodies for Immunometabolism and Tumor Immunology Research - New tools to help researchers understand the tumor and immune cell crosstalk


DANVERS, MA (PRWEB) -- April 12, 2016, Cell Signaling Technology, Inc. (CST), a worldwide provider of antibodies, released four new monoclonal antibodies relevant to the rapidly growing fields of immunometabolism and tumor immunology.

CST has released Arginase-1 (D4E3M™) XP® #93668LAG3 (D2G4O™) #15372ICOS (D1K2T™) (IHC Specific) #89601, and PD-L1 (D5V3B) (Mouse Specific; IHC Specific) #64988 rabbit monoclonal antibodies (mAbs). These rabbit mAbs complement CST’s expanding portfolio of products that support tumor immunology research, including antibodies detecting the PD-1/PD-L1 family of immune checkpoint proteins, as well as metabolic targets, such as IDO, that have been proposed to promote immune suppression within the tumor microenvironment. Introduction of ICOS rabbit mAb also highlights the growing list of antibodies that detect co-stimulatory molecules, such as CD40L, OX40, and OX40L that research studies have demonstrated to have a role in augmenting anti-tumor immune responses.

All four newly released antibodies are recommended for immunohistochemistry (IHC), an application that helps visualize protein expression in the context of preserved tissue architecture, which is key to the translational research community interested in the study of tumor immunology.

Notably, the newly released Arginase-1 rabbit mAb exhibits mouse as well as human reactivity, while the new rabbit mAb targeting PD-L1 demonstrates exclusive specificity to mouse tissue, a critical feature to enable pre-clinical studies, typically carried out in murine models of disease.

CST’s recent announcement introducing the company’s capabilities to produce stringently characterized GMP-grade recombinant rabbit monoclonal antibodies further reinforces the impact that Arginase-1, LAG3, ICOS, PD-L1, and other related antibodies from CST could have on fostering the transition from basic to translational research.

“With the release of these antibodies, we are continuing to build on a rich repertoire of products that are highly enabling to the research community interested in tumor immunology. Our goal is to help scientists understand how tumors interact with the cells of the immune system and how ancillary immunosuppressive factors promote tumor growth. We hope that this understanding may help inform better treatment strategies for many cancers,” said Michael J. Comb, CEO of CST.

Read the whole article here

Product has been added to your cart.